The Asia Pacific Insomnia Market would witness market growth of 4.9% CAGR during the forecast period (2022-2028).
The introduction of technologically advanced medical devices, the rise in the geriatric population, the availability of patented molecules on the market, potential drugs in the clinical pipeline, and potential drugs all have an impact on the growth of the insomnia therapeutics market. Also, nowadays people are becoming more aware of the ill effects of sleep deprivation and thus are well aware of insomnia and its effect.
An irregular bedtime schedule, stimulating activities right before bed, an uncomfortable sleeping environment, as well as using the bed for work, eating, or watching TV are all examples of poor sleep habits. The sleep cycle can be disrupted by using smartphones, TVs, computers, video games, or other screens right before bed which may lead to insomnia. A small snack before bed is acceptable, but if someone eats too much, they might feel physically uncomfortable when lying down. Heartburn, or the backflow of acid & food into the esophagus after eating, is another common condition that can keep people awake.
After the COVID-19 pandemic, 'regular'people were exposed to 'exceptional events,'which led to mental health issues. There are numerous presentations, including emotional issues such as anxiety & sadness, physiologic effects like sleep disruptions and hunger, severe mental illness, and substance abuse. A small percentage of people with these symptoms may encounter serious mental health issues that necessitate additional mental health care, but the majority only experience mild, transient symptoms.
This group may include young children, pregnant women, the elderly, people who already have a mental illness, people who live alone. Another critical element is how the pandemic has affected first aid workers psychologically. The pandemic & widespread social and economic destruction have had a mental toll on society that is unprecedented in modern times, and this is what is fueling the expansion of the insomnia market in this region.
The China market dominated the Asia Pacific Insomnia Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $428.3 million by 2028. The Japan market is anticipated to grow at a CAGR of 4.3% during (2022-2028). Additionally, The India market would experience a CAGR of 5.5% during (2022-2028).
Based on Distribution Channel, the market is segmented into Hospital, Retail, and Others. Based on Therapy Type, the market is segmented into Pharmacological and Non-Pharmacological.Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.
The introduction of technologically advanced medical devices, the rise in the geriatric population, the availability of patented molecules on the market, potential drugs in the clinical pipeline, and potential drugs all have an impact on the growth of the insomnia therapeutics market. Also, nowadays people are becoming more aware of the ill effects of sleep deprivation and thus are well aware of insomnia and its effect.
An irregular bedtime schedule, stimulating activities right before bed, an uncomfortable sleeping environment, as well as using the bed for work, eating, or watching TV are all examples of poor sleep habits. The sleep cycle can be disrupted by using smartphones, TVs, computers, video games, or other screens right before bed which may lead to insomnia. A small snack before bed is acceptable, but if someone eats too much, they might feel physically uncomfortable when lying down. Heartburn, or the backflow of acid & food into the esophagus after eating, is another common condition that can keep people awake.
After the COVID-19 pandemic, 'regular'people were exposed to 'exceptional events,'which led to mental health issues. There are numerous presentations, including emotional issues such as anxiety & sadness, physiologic effects like sleep disruptions and hunger, severe mental illness, and substance abuse. A small percentage of people with these symptoms may encounter serious mental health issues that necessitate additional mental health care, but the majority only experience mild, transient symptoms.
This group may include young children, pregnant women, the elderly, people who already have a mental illness, people who live alone. Another critical element is how the pandemic has affected first aid workers psychologically. The pandemic & widespread social and economic destruction have had a mental toll on society that is unprecedented in modern times, and this is what is fueling the expansion of the insomnia market in this region.
The China market dominated the Asia Pacific Insomnia Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $428.3 million by 2028. The Japan market is anticipated to grow at a CAGR of 4.3% during (2022-2028). Additionally, The India market would experience a CAGR of 5.5% during (2022-2028).
Based on Distribution Channel, the market is segmented into Hospital, Retail, and Others. Based on Therapy Type, the market is segmented into Pharmacological and Non-Pharmacological.Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Currax Pharmaceuticals LLC (Currax Holdings USA LLC), Eisai Co., Ltd., Merck Group, Pfizer, Inc., Vanda Pharmaceuticals, Inc., Cadila Healthcare Ltd. (Zydus Cadila), Sanofi S.A., Viatris, Inc., Takeda Pharmaceutical Company Limited, and Purdue Pharma L.P.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital
- Retail
- Others
By Therapy Type
- Pharmacological
- Non-Pharmacological
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Eisai Co., Ltd.
- Merck Group
- Pfizer, Inc.
- Vanda Pharmaceuticals, Inc.
- Cadila Healthcare Ltd. (Zydus Cadila)
- Sanofi S.A.
- Viatris, Inc.
- Takeda Pharmaceutical Company Limited
- Purdue Pharma L.P.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Insomnia Market by Distribution Channel
Chapter 5. Asia Pacific Insomnia Market by Therapy Type
Chapter 6. Asia Pacific Insomnia Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Currax Pharmaceuticals LLC (Currax Holdings USA LLC)
- Eisai Co., Ltd.
- Merck Group
- Pfizer, Inc.
- Vanda Pharmaceuticals, Inc.
- Cadila Healthcare Ltd. (Zydus Cadila)
- Sanofi S.A.
- Viatris, Inc.
- Takeda Pharmaceutical Company Limited
- Purdue Pharma L.P.
Methodology
LOADING...
